Healthcare Industry News: thrombosis
News Release - June 17, 2008
The Medicines Company Hires Glyn R. Parkin as Senior Vice President, International OperationsPARSIPPANY, N.J.--(HSMN NewsFeed)--The Medicines Company (NASDAQ: MDCO ) today announced that Glyn R. Parkin has joined the Company as Senior Vice President, International Operations. Working with other senior leaders of the Company, Parkin will be responsible for the design, implementation and leadership of the international organization. He will be responsible for the establishment of functioning, capable organizations and business operations in new territories, and then transitioning those operations to the current business unit structure of the organization.
“I am very pleased to be joining The Medicines Company at such an exciting time,” said Mr. Parkin. “The opportunity to expand the Company into global markets is a great and challenging one. I am looking forward to working with the leadership team of The Medicines Company as we create an international organization that develops new ways to effectively meet the unique needs of our global customers.”
Parkin has been in the pharmaceutical industry for over 25 years, all of that time with Eli Lilly and Company. Most recently, he served as Executive Director Marketing, European Operations of the Lilly Europe executive leadership team, where he had overall functional responsibility for marketing including marketing research, sales force strategy and operations, and strategic alliances. In addition, he led three centralized European marketing teams in oncology, diabetes, and thrombosis. He previously held several sales and marketing leadership positions in the UK, as well as eight years in Indiana where he served as global marketing director for Lilly Diabetes Care and led their neuroscience division.
“Given our vision of being a global leader in critical care medicine, we are thrilled to have Glyn bring his strong expertise to The Medicines Company”, said John Kelley, President and Chief Operating Officer of The Medicines Company. “Glyn’s depth of experience in the pharmaceutical industry and his operational experience throughout the world will be an invaluable asset as we build our global organization.”
About The Medicines Company
The Medicines Company (NASDAQ: MDCO ) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Company also has two products in late-stage development, CleviprexTM (clevidipine butyrate) injectable emulsion and cangrelor. The Company's website is www.themedicinescompany.com.
Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of Angiomax; the Company's success in taking over the commercial functions previously performed by Nycomed in Europe and the effects of exchange rate fluctuations and other international economic, political and other risks. These and other risk factors are detailed from time to time in the Company’s periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company’s Quarterly Report on Form 10-Q, filed on May 12, 2008, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.
Source: The Medicines Company
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.